SuperworthEnvoy Medical price to sales ratio COCH
Market value divided by revenue over the last twelve months, since 2024.
- Today, Oct 23, 2026
- n/m
- a sliver of sales
- Last meaningful
- 195×
- Apr 2026
- Peer median
- 1.9×
Envoy Medical's price to sales ratio is not a meaningful number today: a multiple this high rests on a sliver of sales.
It was last meaningful in Apr 2026, at 195×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 195× | 65.3× | 195× |
| 2025 | 101× | 68.1× | 170× |
| 2024 | 117× | 117× | 196× |
Against its peers
Companies in Medical - Instruments & Supplies nearest Envoy Medical's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| COCHEnvoy Medical | n/m |
| NEPHNephros | 1.9× |
| APTAlpha Pro Tech | 0.9× |
| KEQUKewaunee Scientific | 0.3× |
| PDEXPro DEX | 2.6× |
| UTMDUtah Medical Products | 6.5× |
| INFUInfuSystem | 1.9× |
| EMBCEmbecta | 0.4× |
| Peer median | 1.9× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Envoy Medical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.